Assessment of 21-[18F]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas

F. Dehdashti, A. H. McGuire, H. F. Van Brocklin, B. A. Siegel, D. P. Andriole, L. K. Griffeth, Martin Gilbert Pomper, J. A. Katzenellenbogen, M. J. Welch

Research output: Contribution to journalArticle

Abstract

We have used 21-[18F]fluoro-16α-ethyl-19-norprogesterone (FENP) for imaging progestin receptors by PET in patients with primary carcinoma of the breast. In vitro binding and in vivo tissue distribution studies in rats have shown that FENP has high specific activity, high affinity for progestin receptors, and receptor-mediated uptake in target tissues. Eight patients with primary breast carcinoma were studied. Breast carcinoma was identified correctly in 50% of the patients with progestin-receptor-positive tumors; however, the FENP uptake was not correlated with progestin-receptor levels. We noted a low target-to-background ratio in humans, with high relative activity in the spine, blood pool, and normal breast tissue. Our findings indicate that FENP is not a suitable agent for imaging progestin receptors in humans.

Original languageEnglish (US)
Pages (from-to)1532-1537
Number of pages6
JournalJournal of Nuclear Medicine
Volume32
Issue number8
StatePublished - 1991
Externally publishedYes

Fingerprint

Radiopharmaceuticals
Progesterone Receptors
Electrons
Breast Neoplasms
Tissue Distribution
Breast
Spine
21-fluoro-16-ethyl-19-norprogesterone
19-norprogesterone
Neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Dehdashti, F., McGuire, A. H., Van Brocklin, H. F., Siegel, B. A., Andriole, D. P., Griffeth, L. K., ... Welch, M. J. (1991). Assessment of 21-[18F]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. Journal of Nuclear Medicine, 32(8), 1532-1537.

Assessment of 21-[18F]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. / Dehdashti, F.; McGuire, A. H.; Van Brocklin, H. F.; Siegel, B. A.; Andriole, D. P.; Griffeth, L. K.; Pomper, Martin Gilbert; Katzenellenbogen, J. A.; Welch, M. J.

In: Journal of Nuclear Medicine, Vol. 32, No. 8, 1991, p. 1532-1537.

Research output: Contribution to journalArticle

Dehdashti, F, McGuire, AH, Van Brocklin, HF, Siegel, BA, Andriole, DP, Griffeth, LK, Pomper, MG, Katzenellenbogen, JA & Welch, MJ 1991, 'Assessment of 21-[18F]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas', Journal of Nuclear Medicine, vol. 32, no. 8, pp. 1532-1537.
Dehdashti, F. ; McGuire, A. H. ; Van Brocklin, H. F. ; Siegel, B. A. ; Andriole, D. P. ; Griffeth, L. K. ; Pomper, Martin Gilbert ; Katzenellenbogen, J. A. ; Welch, M. J. / Assessment of 21-[18F]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. In: Journal of Nuclear Medicine. 1991 ; Vol. 32, No. 8. pp. 1532-1537.
@article{3de8a84d008c475682e7ec4c92f7669c,
title = "Assessment of 21-[18F]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas",
abstract = "We have used 21-[18F]fluoro-16α-ethyl-19-norprogesterone (FENP) for imaging progestin receptors by PET in patients with primary carcinoma of the breast. In vitro binding and in vivo tissue distribution studies in rats have shown that FENP has high specific activity, high affinity for progestin receptors, and receptor-mediated uptake in target tissues. Eight patients with primary breast carcinoma were studied. Breast carcinoma was identified correctly in 50{\%} of the patients with progestin-receptor-positive tumors; however, the FENP uptake was not correlated with progestin-receptor levels. We noted a low target-to-background ratio in humans, with high relative activity in the spine, blood pool, and normal breast tissue. Our findings indicate that FENP is not a suitable agent for imaging progestin receptors in humans.",
author = "F. Dehdashti and McGuire, {A. H.} and {Van Brocklin}, {H. F.} and Siegel, {B. A.} and Andriole, {D. P.} and Griffeth, {L. K.} and Pomper, {Martin Gilbert} and Katzenellenbogen, {J. A.} and Welch, {M. J.}",
year = "1991",
language = "English (US)",
volume = "32",
pages = "1532--1537",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

TY - JOUR

T1 - Assessment of 21-[18F]fluoro-16α-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas

AU - Dehdashti, F.

AU - McGuire, A. H.

AU - Van Brocklin, H. F.

AU - Siegel, B. A.

AU - Andriole, D. P.

AU - Griffeth, L. K.

AU - Pomper, Martin Gilbert

AU - Katzenellenbogen, J. A.

AU - Welch, M. J.

PY - 1991

Y1 - 1991

N2 - We have used 21-[18F]fluoro-16α-ethyl-19-norprogesterone (FENP) for imaging progestin receptors by PET in patients with primary carcinoma of the breast. In vitro binding and in vivo tissue distribution studies in rats have shown that FENP has high specific activity, high affinity for progestin receptors, and receptor-mediated uptake in target tissues. Eight patients with primary breast carcinoma were studied. Breast carcinoma was identified correctly in 50% of the patients with progestin-receptor-positive tumors; however, the FENP uptake was not correlated with progestin-receptor levels. We noted a low target-to-background ratio in humans, with high relative activity in the spine, blood pool, and normal breast tissue. Our findings indicate that FENP is not a suitable agent for imaging progestin receptors in humans.

AB - We have used 21-[18F]fluoro-16α-ethyl-19-norprogesterone (FENP) for imaging progestin receptors by PET in patients with primary carcinoma of the breast. In vitro binding and in vivo tissue distribution studies in rats have shown that FENP has high specific activity, high affinity for progestin receptors, and receptor-mediated uptake in target tissues. Eight patients with primary breast carcinoma were studied. Breast carcinoma was identified correctly in 50% of the patients with progestin-receptor-positive tumors; however, the FENP uptake was not correlated with progestin-receptor levels. We noted a low target-to-background ratio in humans, with high relative activity in the spine, blood pool, and normal breast tissue. Our findings indicate that FENP is not a suitable agent for imaging progestin receptors in humans.

UR - http://www.scopus.com/inward/record.url?scp=0025925231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025925231&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 1532

EP - 1537

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -